Skip to search formSkip to main contentSkip to account menu

Gemcitabine-Cisplatin Regimen

Known as: gemcitabine/cisplatin regimen 
A chemotherapy combination used to treat malignant mesothelioma, advanced non-small cell lung cancer, advanced bladder cancer, advanced cervical… 
National Institutes of Health

Related topics

Related topics

7 relations
Carcinoma of bladderCervical AdenocarcinomaCisplatinEpithelial ovarian cancer

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Influence of different drug delivery methods for Endostar combined with a gemcitabine/cisplatin regimen in locally advanced or metastatic lung squamous cell carcinoma
Abstract Continuous endovenous administration of Endostar (CE) gradually replaced drip intravenous administration of Endostar (DE… 
2013
2013
Docetaxel as second line after failure of gemcitabine/cisplatin regimen in advanced and/or metastatic urinary bladder cancer patients in Egypt
There were an estimated 72.570 new cases and 15.210 deaths from bladder cancer in 2013. It represents 4.4% of all new cancer… 
2006
2006
A trial of gemcitabine (gems) in combination with cisplatin for treatment of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
15505 Aims: To determine the efficacy of gemcitabine in combination with cisplatin, and to assess the safety profile of the… 
2005
2005
[A randomized clinical trial of gemcitabine plus cisplatin compared with gemcitabine plus vinorelbine in the treatment of non-small cell lung cancer].
BACKGROUND Although platinum-based chemotherapy has become a standard treatment for non-small cell lung cancer (NSCLC), its… 
2004
2004
A non-intensive gemcitabine-cisplatin regimen in pancreatic cancer significantly improves quality of life and pharmacoeconomics with high response rates.
8155 AIM: This Prospective Phase II study was undertaken to determine whether a dose-modified gemcitabine-cisplatin regimen… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)